Ladies and gentlemen, thank you for standing by for Cigna's Third Quarter 2016 Results Review. At this time, all callers are in a listen-only mode. We will conduct a question-and-answer session later during the conference and review procedures on how to enter the queue to ask questions at that time. As a reminder, ladies and gentlemen, this conference, including the question-and-answer session, is being recorded. We'll begin by turning the conference over to Mr. Will McDowell. Please go ahead, Mr. McDowell.

Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. Joining me this morning are David Cordani, our President and Chief Executive Officer; and Tom McCarthy, Cigna's Chief Financial Officer. In our remarks today, David and Tom will cover a number of topics, including Cigna's third quarter 2016 financial results, as well as an update on our financial outlook for 2016. As noted in our earnings release, when describing our financial results, Cigna uses first certain financial measures which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. Specifically, we use the term labeled adjusted income from operations and earnings per share on this same basis as our principal measures of financial performance. A reconciliation of these measures to the most directly comparable GAAP measure, shareholders' net income, is contained in today's earnings release, which is posted in the Investor Relations section of cigna.com. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2016 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC. Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. Regarding our results, I note that in the third quarter, we recorded two charges to shareholders' net income, which we reported as special items. The first special item was an after-tax charge of $46 million or $0.18 per share for merger-related transaction costs. The second special item was an after-tax charge of $25 million or $0.10 per share related to a litigation matter. As described in today's earnings release, special items are excluded from adjusted income from operations in our discussion of third quarter 2016 results. Also, consistent with past practices, when we make any prospective comments on earnings or EPS outlook, we will do so on a basis that excludes the impact of any future capital deployment or additional prior-year development of medical costs. And with that, I will turn the call over to David.

Thanks, Will, and good morning, everyone. In my remarks today, I'll begin with a review of highlights from the third quarter. I will also discuss how our ability to anticipate and meet customer and client needs through innovation, engagement and value-based programs continue to drive our business performance. Then I'll discuss how our well-positioned businesses continue to deliver strong results for the benefit of our shareholders and how we are driving improvements for our businesses that are currently underperforming their potential. We were doing all of this while we continue to prepare for the future by investing in capabilities that meet customers' needs and while we continue to support the litigation process with our proposed Anthem combination. Next, Tom will provide more detail around our third quarter financial performance and our full year outlook. And following your questions, I'll conclude our conversation with just a few closing remarks. Let's begin with some highlights from the quarter. Our third quarter 2016 consolidated revenue increased 5% to $9.9 billion over the third quarter 2015. We reported adjusted income from operations for the third of $503 million or $1.94 per share reflecting strong performance in our Commercial Health Care and Global Supplemental Benefits businesses and improving results in our Group Disability and Life segment. Our actions continue to be guided by our proven strategy of Go Deep, Go Global, Go Individual, with a focus on anticipating and meeting the needs of our customers and clients through ongoing innovation and a commitment to being a trusted partner, as well as continuing investments for future growth and capabilities, which deliver affordable, personalized solutions and further expand our geographic reach. Around the world, individuals are seeking access to quality health care and sense-of-security programs that are both of high quality and affordable. At the same time,…

Thanks, David. Good morning, everyone. In my remarks today, I will briefly review key aspects of Cigna's third quarter 2016 results and discuss our outlook for the full year. Key financial highlights in the quarter are: consolidated revenues of $9.9 billion, consolidated earnings of $503 million, quarterly earnings per share of $1.94, and continued strong free cash flow and financial flexibility. This quarter's result reflects continued strong revenue and earnings contributions from our Commercial Health Care and Global Supplemental Benefits businesses and improved results in our Group Disability and Life business. Regarding our business segments, I will first comment on Global Health Care. Third quarter premiums and fees in Global Health Care grew to $6.8 billion. Third quarter earnings were $416 million, reflecting continued strong performance in our Commercial business driven by customer growth, strong specialty results and favorable medical cost outcomes. Offsetting these strong Commercial results were elevated costs in our Government business related to our CMS audit response and some loss ratio pressure primarily in our Medicaid offerings in Texas and Illinois. Turning to our Global Supplemental Benefits business, premiums and fees grew 9% and earnings of $81 million represent growth of 31% quarter-over-quarter or 25% on a currency-adjusted basis, reflecting business growth and strong operating expense discipline. This business continues to achieve attractive growth and profitability as we deliver value to our customers with personalized and affordable offerings in the supplemental benefit space. For Group Disability and Life, third quarter results reflect premium and fee growth of 4% over third quarter 2015. Third quarter earnings in our Group business were $53 million, reflecting stabilized claim experience in our Life book of business and sequential improvement in disability results as the claim process modifications we made earlier this year continue to mature. Additionally, we completed our annual Disability…

Our first question comes from Matt Borsch with Goldman Sachs. You may ask your question Matthew Borsch - Goldman Sachs & Co.: Yes. Good morning. I was hoping you could give us some more detail on how you're doing with the Group Insurance business. Obviously, the earnings came in better than we were expecting for this quarter. What should we expect – realizing you've given us a range, what should we expect directionally for the fourth quarter and going into 2017?

Good morning. It's David. Just by way of direction, first, we're pleased with the improvement and performance in the third quarter. As we indicated previously, we expect the improvements to continue to be driven throughout the third quarter, fourth quarter and into 2017. There's always some variability in it, hence the range for the business outlook for the full year, but our expectation is throughout 2017, we'd see continued improvement and stabilization in our Disability business and putting us in the right step-up position as we look to 2018. Adding to that, as we look to 2017, we would expect stable and consistent Life results. And I'd note that we saw an appropriate step up in those results in the third quarter. Matthew Borsch - Goldman Sachs & Co.: So, results so far on the Life side would confirm your earlier view that it was a once every decade or several years' fluctuation rather than something systemic?

Matthew, as you recall from the second quarter call, we indicated that the really significant spike took place quite early in the second quarter. And we even saw a reversion back toward the latter part of the second quarter. That pattern continued through the third quarter. We're pleased with our Life results and expect that to continue as we look forward. Matthew Borsch - Goldman Sachs & Co.: And would you say – at this point, would you think that this – in terms of getting back to the – can you get back to the margin that you were at in the 2013 to 2015 time period for your Group Insurance business overall by the time you get to 2018?

Matthew, clearly, we're not giving you 2018 guidance, but first, by way of backdrop, the Disability portion of this business is a very strong and well-performing business that focuses on productivity solutions for employers. At this point, we fully expect that as we fully mature this model, we will be able to get back to our sustained margin goals. Matthew Borsch - Goldman Sachs & Co.: Let me just ask one question on a different topic, which is as you look ahead to next year, on Medicare and the Star score results, what odds do you think you'll have of either getting CMS to maybe rethink the approach that they'd taken on the Star scores for impacting you in 2018 versus what you can do whether it's cross-walking or rather activities to offset that?

Matthew, I actually compliment your efficiency getting in so many questions. Relative to the Stars Rating, by way of backdrop, we're pleased and proud with the position we've developed for ourselves. 2016, 60% of our lives were four STAR+PLUS. 2017, 75%. Per your comment, the current view is that the Stars Rating would step down for 2018, specifically because of the audit process. To be quite clear here, we do not agree with those conclusions, nor do we accept those. In fact, our clinical and service measures reinforce a very positive outcome for the benefit of our seniors and our physician partners. And we're going to use a variety of approaches to resolve that issue, because again, we don't accept that outcome.

Thank you, Mr. Borsch. Our next question comes from A.J. Rice with UBS. You may ask your question.

Thanks. Hello, everybody. First, a detailed question and a follow-up. The $60 million of headwind around the government business, I know part of it's audit cost and part of it sounds like it's this Medicaid issue. I think, last quarter, you said the audit costs were about $30 million. Were they similar in this quarter? And can you expand a little bit on the Medicaid issue?

Sure, A.J. So, your recollection from last quarter is right, and I'd say the cost in this quarter were little higher than that. And if we look at the $60 million, which was the change in expectation for the full year, I'd split that about 50-50 between Medicaid and additional remediation costs.

Any color on what's happening in Medicaid?

Oh, sure. So, first, again, let's put it in context. Medicaid is a small business for us, essentially just the dual SNP programs in Texas and the dual demonstration project in Illinois. And we did report an increased MCR in both Texas and Illinois this quarter. Different dynamics in each market. Texas included pressure from the long-term support service costs. In Illinois, we're seeing some rate pressure and more significant mix of higher-acuity patients than we'd expected.

Okay. And maybe my follow up to stay sort of in the government area. it's been a while since we had a company have to go through the Open Enrollment under sanctions. Can you just remind us on the ground what can you do to retain your membership and keep others from going after that? And when we get through the end of Open Enrollment, when you're thinking about 2017, is whatever enrollment you end up with, is that where you think you'll be for the year? I mean I guess, that entails when you think you might get resolution on the sanctions as well, but any thoughts on that would be helpful.

A.J., good morning. Relative to your framing of your question. First, by way of backdrop, you're correct. Our working assumption is that we will not be participating in the Open Enrollment period. Specific to the actions, I'm not going to delineate the specific actions you can or cannot take. There's clear rules in terms of what you can do, in terms of what's the marketing versus retention activities. I think the most important thing to highlight is within our model, you'll recall that our model is largely based where the majority of our lives are in terms of very mature physician collaborative models, hence those customers or members have very deep relationships with those physician groups. That is a highly retentive tool. Not perfect, but it's a highly retentive tool, because there's deep relationships that have been built, there's expanded services and the like. So, while we expect attrition, and as I noted in my prepared remarks, we're planning for a revenue headwind in 2017 that will be offset by the attrition of the remediation costs. We expect retention to perform better than the historical norms of a sanctioned environment. As it relates to 2017, as soon as we're off sanctions, we'll be back in the monthly enrollment process, and we look forward to that environment.

Okay. All right then. Thanks a lot.

Thank you, Mr. Rice. Our next question comes from Josh Raskin with Barclays. Your line is open. You may ask your question.

Great. Thanks. Just want to start on the comments around 2017 being attractive financially and maybe juxtapose that with the 10% to 13% long-term growth. Is that attractive, meaning you expect to be within that range? And then what base should we be using for 2016? Maybe if Tom could give us sort of a run rate 2016 once we take out all the remediation costs that are extra, and any favorable development, or negative development as well, and maybe the Life and Disability side.

Josh, good morning. It's David. Let me give you just a little bit more color in terms of the drivers, as we think about moving from 2016 to 2017. And I appreciate your reframing our long-term commitment of the 10% to 13% on average, which we've delivered on average over the last half a dozen years. Specifically, we see three. We call it the three largest, meaningful tailwinds that are specific and compelling. Number one is the continued leverage of our well performing businesses, specifically our U.S. Employer Health Care business, and our Global Individual business, where we expect to continue to deliver attractive both revenue and earnings growth. Second is a meaningful step up in the margin performance of the Group Disability and Life business. And third is margin expansion in the Government business, where, largely, the attrition of the cost profile that we've incurred this year, which was significant will more than offset the revenue headwind. It's important to attach on top of that, that's going to take place under one or two environments: will either be in a so called Plan A, where we're able to effectuate the combination and we're stepping into a different environment; or a so-called Plan B, where the government will stop and impede us in terms of the ability to combine. In a Plan B scenario, our estimate is towards the latter part of 2017, we'll have between $7 billion and $14 billion of deployable capital, which is made up of about $5 billion of free cash at the latter part of 2017, leverage that we could step up to one threshold if we're going to use it solely for internal purposes, dividend buy back and the like. And the higher end of the range is if we're going to use leverage largely to expand our self through M&A capacity. So, taken as a whole, a significant uptick. I don't think it's constructive on this call to try to scroll the numbers around on the underlying run rate. Suffice to say 2016 is a choppy year for us, 2017 will be quite attractive. And if we expect to deliver certain numbers on average since this year is not an average year from a transition, we'd expect to have a very strong performance for 2017.

I'm sorry, David, is there a way to just parse that, maybe you don't have to give what you think the run rate, but just any extraordinary numbers this year? You're talking about the remediation costs. Obviously, that's a – I don't know if that's $70 million or so, or any way to just size the one-timers at least?

Let me give you two chunks to try to be helpful here. Chunk one will go to the remediation cost. Our best estimate for the full year is approximately $100 million after-tax. So, when we talk significant, it's significant because our objective is to effectively and rapidly – and speed is always in the eyes of the beholder, but effectively and rapidly resolve this and use whatever resource is necessary to put this behind us. So, think about $100 million after-tax, which is significant. Secondly, you know us quite well. And you know even with the revised outlook for our Group Disability and Life business, the earnings dislocation there is significant. And if you will just project forward a mindset that our view is a stable and consistent performance of the Life business, that's a meaningful step up. And then continued improvement in the Disability business. There's a significant step up, or an example to your point of a one-time dislocation, when you would compare 2016 to 2017, albeit, we don't expect to be at full earnings potential in 2017 because Disability will ramp throughout the course of the year. Those are two items I'd ask you to focus on.

Okay. Perfect.

Thank you, Mr. Raskin. Our next question comes from Justin Lake with Wolfe Research. You may ask your question.

Thanks. Good morning. First question, just to kind of tie out the whole CMS audit stuff. I wanted to ask, at what point do you think the work's going to be complete here, David? And then for – you put that $100 million number out there for the year. Is there any of it that you think remains in 2017, or does it all go away? And then you talked about being better than average. And I went back to Aetna and Health Net when they were out of the market, and I think they lost about 20% of their membership during Open Enrollment, while they were on sanction. Is that the bogie you're comparing yourself to when you're saying you're going to be better than average? And any kind of way that would give us directionality on that would be great.

Yeah. Justin, a few different comments there. First, by way of context. So, this is obviously a complex undertaking. And as I noted, as the $100 million reinforces, it's complex in terms of what we're confronting here. We confronted an audit process that was changed and modernized for CMS, so a new audit methodology. We operate a business model that functions off the more modern collaborative or value-based environment. And what that means is we have a lot of partners. Think about entities that we work with in partnership to get that value-based environment, and think about the better part of a couple hundred. So, the ability to operate in this more modernized audit environment relative to that, which we believe is a big part of what the future of health care looks like required us to drive some changes. We're driving those changes, and we'll seek to get those resolved in short order. So, we think we're in the latter phases, point one. Two, we believe the large majority of those costs will not be re-occurring, that otherwise will be contributors to 2017's earnings or the margin inflection. And third, we fully expect our retention levels to outperform the numbers that you referenced, largely based on the different orientation we have of our model. And we could look back and look at the retentive nature of our business over a long period of time and those relationships. So, while we expect a revenue headwind that will be meaningful, our revenue headwind projection is not in line with the numbers you made reference to. And we think it's largely driven by the different model we have, whereby once our customers are with us a year or more, they tend to be with us for a long, long time, largely because of those collaborative relationships.

Great. And then just a quick follow-up on the Health Care earnings. I understand, obviously, there are some headwinds and tailwinds going into next year on the Medicare side, but the increase in the remediation costs, I mean, basically, you took down Health Care by $60 million. I'm curious when you – we normally think about your Health Care business as a mid-to-high single-digit grower. Would it be reasonable to think that you'd grow in that capacity off of the original guidance, given that Medicaid and the CMS audit increases would seem to be transitory, or should we think about that growth coming off the new $1.840 billion to $1.870 billion guidance? Thanks.

Justin, we're not providing the detailed guidance for 2017. We look forward to doing that on our year-end call. But I think there's two important points you teased out. One, noted in my prepared comments, we continue to feel quite good about our Employer Health Care business, and that Employer Health Care business has continued to perform well as the marketplace looks for more engagement, more affordability solutions, more partnership solutions. And we would expect to see continued strong performance relative to our top line as well as our bottom line. And I'd ask you to think about our historical performance there. And I think you made reference to that. If you extract out the Government portion of the business, that's been lumpy beyond a shadow of a doubt. And we expect to see a step up in earnings next year, so I'd ask you to pull those two pieces apart as you think about your 2017. Clearly, we'll provide guidance at the end of the year as we go into our fourth quarter call.

Thanks.

Thank you, Mr. Lake. Our next question comes from Gary Taylor with JPMorgan. You may ask your question.

Good morning. Thanks. Just a couple of questions. One, on the same topic, just the progression of the Global Health Care earnings through the year. I just want to make sure I understand. So, if we look at the first quarter, net income in the segment, up about $100 million. 2Q was down $42 million. Third quarter is down $66 million. The issues you've cited through the year have been individual market, Medicaid, the MA audit costs. But then as I look to the fourth quarter, it looks like you're looking for flat to plus $30 million year-over-year. So, just trying to understand that piece, why does it improve in the 4Q on a trend basis?

Gary, a couple of things. First, you've cited the quarter-over-quarter variance in the third quarter. And you've got that right. And that's largely driven by the Medicaid and remediation costs. As we look to the fourth quarter, again the remediation costs we expect to moderate. The fundamentals in the fourth quarter kind of continue to be the same, very strong underlying Employer business, really not much news on the Individual side, a little bit of timing difference in the Group Disability and Life and Global Sub business. But that's generally the picture for the balance of the year.

Okay. Second question, just going back to Disability for a moment, David. I think when you had the issue in the 2Q, you were very clear that in the Disability claims you're not having a frequency issue. It's primarily a duration of claims issue caused by the disruption. So, as we look at this nice sequential improvement, is that where we'd be looking to that claims duration has improved sequentially?

Gary, appreciate the framing. Two dimensions here, so we're at the same convention. There's claims that are presented, there's validated claims, we call those occurrences or open claims, and then there's closed claims. So, point one is throughout the course of the year, we have not seen a different pattern. Again, we have not seen a different pattern of the volume of claims that present themselves for consideration. So, that's, I think, your first point. As we changed our model, we saw more claims go from that first bucket of potential claims to activated claims, open claims, because of the disruption of our process. So, that's disruption point number one. Disruption point number two is more claims stayed open or active for an elongated period of time because of the disruption. If I understand your question, if you think about the third quarter, we're seeing, again, no change in the number that are presenting themselves for consideration but improvement in that bucket two and bucket three, which are validated claims that are opened, and the rate and pace in which claims are closed. And we expect over time that pattern to continue.

Okay. Perfect. Thank you

Thank you Mr. Taylor. Our next question comes from Christine Arnold with Cowen. You may ask your question. Christine Arnold - Cowen & Co. LLC: Hi, there. With respect to the Medicare Advantage book, was the MLR elevated there at all? And as we go through Open Enrollment and experience some attrition, should we expect any impact on the MLR owing to the sanctions, or is it just a revenue issue?

Christine, it's Tom. So, I would answer your last question first. I would expect the impact from sanctions will largely be in revenue. The position engagement model in HealthSpring continues to deliver strong medical costs consistently throughout the year. On a year-to-date basis the Medicare results are about flat MCR-wise, which again reflects that consistent strong performance as we commented on last time. Last time, there's a little bit of a higher MCR in some of the expansion markets, some of the less engaged markets, but generally consistent with our expectations for the year. Christine Arnold - Cowen & Co. LLC: And it sounds like the improvement from second to third quarter in D&L was – both Life and Disability. Is there any way to parse out how much we saw improvement in Life versus Disability and – so, we can get a sense for how much more Disability is going to drive improvement or – and have we maximized our Life experience? Are we back to normal there?

Well – look, again, last quarter, we highlighted we had significant variability in Life, so obviously more of the improvement sequentially has come from Life just getting back to normal, and in fact that kind of is the headline. Life business, back to normal expectations, Disability improving. Christine Arnold - Cowen & Co. LLC: Great. Thank you.

Thank you Ms. Arnold. Our next question comes from Kevin Fischbeck with Bank of America Merrill Lynch. You may ask your question.

Sure. I want to go back to the headwinds and tailwinds for 2017. I guess, you didn't mention Medicaid improvement as a tailwind to 2017, so does that mean that you're not expecting improvement there? And then as far as the headwind, I think the only headwind I heard you mention was MA membership attrition. Is that really kind of the only meaningful headwind that you expect for 2017?

Kevin, good morning. It's David. You're correct. There's a variety of items, we didn't mention. So, there's always some smaller puts and takes. What we tried to call out were the three compelling major drivers. So, there's going to be other small puts and takes. And you should expect that if we're underperforming in Medicaid, we'd expect to take actions to slightly improve that as we move forward. But it's a small portion of our business, and in the scope of the moving parts that we talked about, those are the three items I'd ask you to consider relative to the fundamentals, with the fourth being the just tremendous capital deployment opportunity that sits in front of us.

Okay. But it sounded like you said that the Medicaid was half of the government issue in the quarter and that you took down Health Care by $60 million, so it's not right to think that Medicaid was a $30 million drag?

Relative to the current year, we're feeling the pressure relative to the Medicaid number. All the other fundamentals are holding. If you look at the year to date, our Medicare number, as Tom noted, is performing cleanly year-over-year in totality with some puts and takes. Our PDP results improved somewhat. Our Medicaid results eroded somewhat. As we project forward to next year, again, we would expect to take actions to improve the Medicaid numbers, but the size of that delta in a well over $2 billion after-tax earnings franchise, what we're trying to call out here, these are the three discrete drivers that are most significant. There'll be some other puts and takes, absolutely. And you're correct, we would expect to improve that result as well.

Okay. And I guess my last question on your bids for next year, for MA, with the HIPAA expiring and also with the sanction, you get a lot of moving parts as to how you'd want to do this. It sounds like you're saying margin improvement in MA is driven more by the CMS sanction costs winding down rather than material MLR improvement. Wasn't sure how you – did you bid for margin? Did you bid kind of assuming a stable margin for next year? What were your thoughts there going into next year?

With an eye toward 2017, obviously, when we had to put the bids in, we understood the environment we were in. We were already through the audit process. So, we knew the sanctions, et cetera. If you look back historically, we typically positioned ourself for more stable offerings, consistent benefits. As I referenced before, long-term customer relationships are an important part of our model, because it facilitates the interaction back and forth through the value-based offerings. Clearly, we sought to improve margins in some of the markets that were underperforming. With a portfolio our size, there's always opportunities in some select markets to improve margins, but that's a market-by-market approach. So, think guiding force, stable benefits, stable offerings, the customer-first orientation, working with our physician collaboratives, looking at all the tools that are available to us especially in the markets that may be underperforming. Some of those are the less mature market, so we took some actions in some of the less mature markets, and we expect to see a little bit more disruption there, but margin improvement that would take place, but by and large, stable offerings.

Okay. Thanks.

Thank you, Mr. Fishbeck. Our next question comes from Ralph Giacobbe with Citi. You may ask your question.

Thanks. Good morning. I just wanted to go back to the MA side. You talked about $100 million in costs coming back to you after sanctions are lifted. And you said that, that's going to be more than offset any losses in Enrollment. But back to the envelope, we're estimating that's about 15,000 lives and off your base, which suggests about a 3% drop, in Enrollment. When I look at the last couple of quarters, you've had sort of a 2% to 3% drop sequentially sort of outside of Open Enrollment. So, just want to see if I'm missing anything and just your comfort around those expectations.

Ralph, good morning. It's David. I'm not going to go through the moving parts at this point. We'll provide full 2017 guidance at the end of the year, as we go through our fourth quarter call. The three headlines here are as follows: One, we expect better than market retention, because we've typically delivered better than market retention levels from our customers specifically tied to the collaborative model. You could actually look at – to your point, you can look at our attrition rates throughout the course of the year as we've been able to manage the business. Point two is the remediation costs will essentially – the large majority of those costs will attrit next year, which will offset the earnings implication. Broad sweeping numbers, we expect to grow the franchise in aggregate revenue numbers because of the strength of the business, as I referenced before: the U.S. Commercial Employer business; the Global Supplemental Benefits business; our Specialty portfolio, et cetera. And that will more than offset the revenue implications here as well. Lastly, order of magnitude, you could think about $1 billion of revenue that unfortunately currently is low margin. We'll step the margin up, and that will more than offset the earnings implication from that as we look through the attrition, both the end-of-month attrition for this year as well as the Open Enrollment attrition for next year.

Okay. And then just my follow up, just want to go into the Commercial MLR a little bit more. You mentioned taking down sort of cost trend. Maybe go through some of the components of what you're seeing as the drivers there and how that's impacting – or maybe how that impacted how you priced and thought about 2017. Thanks.

Hi, Ralph. It's Tom. So, obviously, we're very pleased with the medical trend results. We're continuing to build on a competitively attractive record here. And since most of our commercial customers are in self-funded arrangements, they directly benefit from this well-managed trend. So, absent the components, the experience to-date generally shows all of our trend components in the low to mid-single digits, so were pretty happy with that results. As far as impact on pricing, our philosophy has typically and remains consistent to anticipate medical cost trend in our pricing. And effectively, we're seeing great results in delivering medical cost trend and a good trajectory for this business going forward.

Okay. Thank you.

Thank you, Mr. Giacobbe. Our next question comes from Ana Gupte with Leerink Partners. You may ask your question.

Yeah, thanks. Good morning. So, again, following up on the Government loss ratio. This year, you had year-over-year compared to last year give or take maybe 150 basis points or so of deterioration. Can you par that, how much of that came from this Texas, Illinois duals issue versus the Medicare advantage deterioration or Part D deterioration? And then given that you've been under what – CMS now apparently has a new claims audit process, so next year as you look at recovery and the MA and some of the Part D piece of it on loss ratio, how much of that is recoverable, or is this kind of the new normal because of a more stringent claims audit process?

Ana, it's Tom. Rather than getting into all the pieces here, let me give you the higher-level message. The quarter-over-quarter deterioration you mentioned, that 160 basis points, 170 basis points. That's all attributable to Medicaid and the difference in less favorable prior development this year compared to last year. So, I wouldn't be anticipating that we'd be seeking significant improvements in the Medicare Advantage loss ratio going into 2017. We'd expect to have significant – continued ongoing strong performance there. And as far as splitting the difference in the variance in the quarter it splits about 60/40. Medicaid, the more significant variance is about 40%. A little bit of minor puts and takes other than that, but about 40% related to the difference in prior year.

And on the latter part of your question, I'd ask you not to think about an impact of the audit on the sustainable loss ratio. I think I heard you say the claim audit process having an impact on the loss ratio going forward. We do not expect any implication on the sustainable of the loss ratio there. We have operating expenses, which you referenced that we had to incur to make process changes, but there are not fundamental differences of our cost, or quality, or clinical performance measures in any way, shape, or form we need to worry about there.

Okay. That's helpful. And just going to the Individual side, you don't say much here. The Commercial book's performing very well. I'm estimating you have maybe $800 million to $1 billion or so in premiums. As you look at how sequentially your experience from 2Q to 3Q, what is that telling you about that book, even though it's small compared to your peers? And what does that mean for next year in relation to your bids? And I believe you've entered one more state at least.

Ana, two headlines there. Relative to 2Q to 3Q, essentially consistent, I think is the big picture headline relative to the individual book of business. Relative to next year, important to put a backdrop on it. As you recall, we have been, I'll say, cautious and slow in this space, is the headline. As we've viewed the opening of this marketplace in 2014 is probably being much smaller than projections, not profitable for the industry and choppy or less than stable operationally. And unfortunately, societally, it's proving to be more right than wrong. We entered five markets, and we deliberately and slowly grew to seven markets. As we look to 2017, our initial plan had us growing into 10 markets. After assessing all the market dynamics, we're going to end up in seven markets in 2017, but a different mix where we will shrink our footprint in three markets by leaving three markets on the exchange. And then we'll have a new offering in three different markets, specifically built on our collaborative model. So, some change in the overall profile of our marketplace but a smaller geographic footprint than we were anticipating; we anticipated going from seven to 10 markets. We're going to actually be in seven markets with a different mix, net-net taking it all as a whole. For next year, we're going to expect to see some revenue growth there. We're continuing to plan for a loss in the business, which is what we think is appropriate as we continue to refine our learnings and look to determine whether there's a sustainable future here.

Great. Thanks so much.

Thank you, Ms. Gupte. Our next question comes from Dave Windley, Jefferies. You may ask your question.

Hi. Thanks. Good morning. I wanted to pivot to a couple of questions on International. David, your International Risk business membership growth ticked up pretty nicely in the third quarter. Wondering if that's another bright spot in Global Health Care, and if there's anything in particular to call out there in the growth path of that business? And then over on Global Sup, I guess I'm just interested in kind of an update on the overall strategy and model. Is it basically unchanged and continuing to roll out in additional markets or countries, noting that Korea had an 18% growth in the quarter?

Dave, good morning. So, two headlines here. First, as we noted both through Tom's comments and my comments, continued strong performance of our Global business, that's headline number one. Two different businesses, big picture to think about. One is a largely an employer globally mobile business, where we take care of corporate expats, IGOs, NGOs, et cetera. And we've seen a bit of growth in there that we are pleased with and a bit of continuation of growth there that we're pleased with. That's part of our Global Employer business. And then the Global Supplemental or Global Individual business, where we continue to see strong growth anchored in our strongest market, which is Korea. You referenced a phraseology in terms of is there nothing changed? A pause on that one, because in a dynamic global market, everything's changing all the time. But the core of our business model remains, which is a focus for that business, the Supplemental business, a focus on the individual, understanding their needs, innovating derivative products and having distribution capabilities and unique ways to meet them on a direct fashion, be it telemarketing, be it direct pull-through Internet, be it TV, be it retail base, et cetera. That iterative evolution is what's driving our business growth as the global markets continue to evolve and the global middle class continues to grow. So, looking forward, as we noted, we expect this to continue to be a positive driver for us to 2017 and looking to the future.

Okay. Thank you.

Thank you, Mr. Windley. Our next question comes from Chris Rigg, Susquehanna Financial Group. You may ask your question.

Just wanted to come back to Global Health Care income quickly here. I'm sorry to keep coming back to this, but, I guess, when we think about where you were when you reported second quarter results the end of July relative to what you're looking for now in terms of the remediation costs, I mean, it's a $30 million step up in a pretty short window of time. I guess, I'm just not fully understanding why it increased so rapidly relative to what you were looking for at mid-year.

Well, Chris, it's Tom. Look, we've invested a lot in technology, augmenting staff and engaging consultants to get this done as quickly as possible. And the cost has been substantial. Total costs to-date are in the about $80 million range after tax. As David indicated, we're expecting about $100 million for the full year, so we see the costs have peaked in the third quarter. They have significantly ramped down in the fourth quarter, and that ramp down reflects a more narrowly-focused work effort as we just address the remaining issues. So, that's the general pattern of what's going on here.

Okay. And then just on the two Medicaid issues, I mean, Texas normally has a rate increase September 1, and I can't remember where Illinois stands, but nevertheless, do you think at least in Texas, the rate increase there gets you back to breakeven pretty quickly? And likewise, can you give us a sense for where things stand in Illinois? Thank you.

Yeah. I'd say, in Texas while perhaps there'll be a rate increase that will help us, that's more impacting costs. In Illinois, we'd expect it to be more through rate increase. And we'd expect that to be closer to the beginning of the year. So, all in, again, this is a small business for us, so I think that on the margin, the impact is marginal, but all in, we'd expect to get some improvement in results here.

Thank you.

Thank you, Mr. Rigg. Our last question comes from Michael Newshel with Evercore ISI. You may ask your question.

Hi. Good morning. Thanks for getting me in there. On your decrease to cost trend guidance for the Commercial business, are there any particular utilization categories to call out that drove the decline there in terms of inpatient versus outpatient versus prescription?

Yeah, again, we're pretty happy with the overall results here. I would call out, the driver of the change is largely pharmacy. So, in the pharmacy trend, we're seeing benefit both from the moderation in specialty drug costs and the continued strong performance of our integrated model.

And then maybe just one more on Star Ratings and Medicare Advantage. Given the decline there for the 2018 payment year, what do you think your prospects are for improving those ratings for 2019?

Yeah, Michael. It's David. First, as I indicated previously on the call, we're pleased with the quality indicators, we're able to deliver. So, off a base of 60% for STAR+PLUS in 2016; 75% for STAR+PLUS in 2017. Absolutely not lost in us that the current view is to meaningfully downdraft us for 2018. We do not agree, and therefore do not accept that. Our outcome measures, both service satisfaction and retention, clinical outcomes, physician partnership members do not reinforce that. So, we have a variety of paths in front of us. We seek to address that for 2018 long before we look at 2019. Fundamentally, we would expect to be rewarded for and recognized for the strong performance we're able to deliver as we look to 2018 and 2019.

Great. Thanks, guys.

Thank you, Mr. Newshel. I will now turn the call back over to David Cordani for closing remarks.

Thanks, everyone. So, to conclude our call this morning, I'd like to underscore just a few key points from our discussion. Cigna's third quarter results include meaningful revenue and earnings contributions from our Global Health Care and Global Supplemental Benefits business and improving financial performance in our Group Disability and Life segment. This gives us confidence that we will achieve our full year 2016 outlook and deliver attractive earnings and revenue growth in 2017. We are anticipating and meeting customer and client needs through innovation, engagement and value-based programs, which continue to drive our business performance. We have significant capital resources available for deployment. And our business remains well-positioned to deliver strong results for the benefit of shareholders over the long-term. And finally, we're fortunate to have a passionate and engaged workforce of over 40,000 colleagues around the globe, who are guided by our strategy to drive value for our customers, clients and shareholders each and every day. Again, we thank you for joining our call, and for your investment in Cigna.